SynthesisPloS one2014
Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Compensatory mechanisms for methylglyoxal detoxification in experimental & clinical diabetes.Molecular metabolism · 2018Trial
- Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus.Journal of diabetes research · 2017Trial
- Autonomic neuropathy in diabetes.Archives of endocrinology and metabolism · 2025Review
- Review
- Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review.Diabetology international · 2023 · on this mapReview
- Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis.Biomedicines · 2022Review
- Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review).Experimental and therapeutic medicine · 2021Review
- Current concepts in the management of diabetic polyneuropathy.Journal of diabetes investigation · 2021Review
- From LC-MS/MS metabolomics profiling ofBioinformation · 2021Article
- [Causes, spectrum, and treatment of the diabetic neuropathy].Der Nervenarzt · 2020Review
- Antibacterial properties of 5-substituted derivatives of rhodanine-3-carboxyalkyl acids. Part II.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet.Diabetes & metabolism journal · 2019Review
- Curcumin, Cardiometabolic Health and Dementia.International journal of environmental research and public health · 2018Review
- Loss of Glyoxalase 1 Induces Compensatory Mechanism to Achieve Dicarbonyl Detoxification in Mammalian Schwann Cells.The Journal of biological chemistry · 2017Article
- Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017Review
- Review
- The aldo-keto reductases (AKRs): Overview.Chemico-biological interactions · 2015Review
- Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment.World journal of diabetes · 2015 · on this mapReview
- Identifying Common Genetic Risk Factors of Diabetic Neuropathies.Frontiers in endocrinology · 2015Review
- Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.The review of diabetic studies : RDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAldose reductase inhibitors (ARIs) can block the metabolism of the polyol pathway, and have been used to slow or reverse the progression of diabetic cardiovascular autonomic neuropathy (DCAN). The purpose of this study was to review the effectiveness and safety of ARIs in the treatment of DCAN as determined by five cardiac autonomic neuropathy function tests.
methodsCENTRAL, MEDLINE, EMBASE, Scopus databases (inception to May 2012) were searched to identify randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) investigating ARIs for the treatment of DCAN with an English-language restriction. The data were analyzed using RevMan 5.0, and the heterogeneity between the trials was evaluated using the Cochrane's Q-test as well as the I² test. The type of model (random or fixed) used for analysis was based on heterogeneity. Weighted mean differences (WMD) with 95% confidence intervals (CI) were computed for the five cardiac automatic neuropathy function tests to evaluate the effects.
resultsTen articles met the prerequisites for this review. Analysis of the results showed that ARIs significantly improved function in at least three of the five automatic neuropathy tests, including the resting heart rate variation coefficients (WMD = 0.25, 95%CI 0.02 to 0.48, P = 0.040); the 30∶15 ratio (WMD = 0.06, 95%CI 0.01 to 0.10, P = 0.010) and the postural systolic blood pressure change (WMD = -5.94, 95%CI -7.31 to -4.57, P = 0.001). The expiration/inspiration ratio showed a marginally significant benefit (WMD = 0.05, 95%CI 0.00 to 0.09, P = 0.040). Glycaemic control was not significantly affected by ARIs. Adverse effects of ARIs except for Tolerestat were minimal.
conclusionsBased on these results, we conclude that ARIs could ameliorate cardiac automatic neuropathy especially mild or asymptomatic DCAN but need further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.